Welcome to our dedicated page for Xenetic Biosciences SEC filings (Ticker: XBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DNase platforms, PolyXen drug extensions and early-stage CAR T research make Xenetic Biosciences’ disclosures uniquely detailed—and hard to navigate. Clinical trial updates, royalty waterfalls and dilution clauses often span hundreds of pages, leaving even seasoned analysts searching for context. If you have ever typed “Xenetic Biosciences SEC filings explained simply” into a browser, you already know the challenge.
Stock Titan solves that problem. Our AI parses every document the moment it hits EDGAR, turning jargon into clear takeaways you can act on. Want “Xenetic Biosciences insider trading Form 4 transactions” or need the latest “Xenetic Biosciences quarterly earnings report 10-Q filing”? They appear here with side-by-side AI commentary. Real-time alerts track “Xenetic Biosciences Form 4 insider transactions real-time,” while smart summaries spotlight trial-phase spending, milestone payments and cash-runway projections buried deep in MD&A sections.
Use this page to:
- Access a “Xenetic Biosciences annual report 10-K simplified” with highlighted pipeline risks
- Dive into “Xenetic Biosciences earnings report filing analysis” for revenue from licensing partners
- Monitor “Xenetic Biosciences proxy statement executive compensation” to gauge alignment with shareholders
- Receive “Xenetic Biosciences 8-K material events explained” within minutes of release
- Track “Xenetic Biosciences executive stock transactions Form 4” before key trial readouts
- Save hours by “understanding Xenetic Biosciences SEC documents with AI” rather than line-by-line review
Whether you’re assessing dilution risk, validating NET-targeted trial data or comparing quarter-over-quarter cash burn, our comprehensive coverage and AI-powered summaries keep you ahead without drowning in paperwork.
Xenetic Biosciences, Inc. filed a prospectus supplement for a public offering that would increase its common stock outstanding beyond the 1,542,139 shares reported as of
The filing names Canaccord Genuity LLC as an underwriter and estimates offering expenses payable by the company (excluding underwriting discounts) of approximately
Xenetic Biosciences reported a narrowing net loss driven by lower operating expenses while continuing to receive royalties from Takeda. Royalty revenue was $589,897 for the quarter and $1,183,158 for the six months ended June 30, 2025. The company recorded a net loss of $688,703 for the quarter and $1,591,844 for the six-month period. Cash totaled $4,779,846 at June 30, 2025 and working capital was approximately $4.5 million, while total assets were $5.35 million.
Operating costs fell year-over-year as R&D and general and administrative expenses declined, largely reflecting lower personnel and severance-related items recognized in 2024. Management states existing resources are adequate to fund operations for at least twelve months from issuance of these financial statements, but the company anticipates the need for additional capital longer term to advance its DNase clinical program and other initiatives.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
